Literature DB >> 8566075

Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mice.

M Battegay1, P Fiedler, U Kalinke, F Brombacher, R M Zinkernagel, H H Peter, G Köhler, H Eibel.   

Abstract

Using a pair of gamma 2a/chi immunoglobulin genes, transgenic mice were generated to study tolerance induction in B cells that express IgG2a autoantibodies. The transgenic IgG2a specifically binds CD8 alpha chains of the CD8.2 allotype expressed on the surface of CD8+ T cells, but not CD8 molecules expressed by the CD8.1 allele. Thus, IgG2a transgenic mice expressing the CD8.1 allele were used as controls to monitor B cell development and mice expressing CD8.2 were used to study B cell tolerance. Both types of mice showed transgenic gamma 2a expression on the surface of B cells. Expression of endogenous heavy chain alleles was strongly inhibited in immature B cell subsets, whereas mature B cells co-expressed transgenic gamma 2a and endogenous IgM/D. The transgenic chi chain expression leads only to partial allelic exclusion of endogenous light chains. B cells that express high levels of transgenic CD8.2-specific IgG2a were identified using soluble CD8-Ig. In CD8.1+ and in CD8.2+ mice, we found no differences in expression and maturation of transgenic anti-CD8.2 IgG2a+ B cells. High levels of serum anti-CD8.2 IgG2a antibodies led to the elimination of CD8+ T cells, causing a severe defect in cytotoxic immune responses. These results show that tolerance induction is incomplete in the CD8.2+ mice, either because IgG2a+ B cells are resistant to censoring mechanisms or because the secreted CD8-specific IgG2a antibodies render the CD8 autoantigen inaccessible to the B cells. This contrasts strongly with the efficient induction of B cell tolerance in mice expressing anti-CD8.2 IgM autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566075     DOI: 10.1002/eji.1830260139

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

Review 1.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  Gene dose-dependent maturation and receptor editing of B cells expressing immunoglobulin (Ig)G1 or IgM/IgG1 tail antigen receptors.

Authors:  S L Pogue; C C Goodnow
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

3.  Augmented B lymphocyte response to antigen in the absence of antigen-induced B lymphocyte signaling in an IgG-transgenic mouse line.

Authors:  Rong-Yong Man; Taishi Onodera; Emi Komatsu; Takeshi Tsubata
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

4.  IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta.

Authors:  Ari Waisman; Manfred Kraus; Jane Seagal; Snigdha Ghosh; Doron Melamed; Jian Song; Yoshiteru Sasaki; Sabine Classen; Claudia Lutz; Frank Brombacher; Lars Nitschke; Klaus Rajewsky
Journal:  J Exp Med       Date:  2007-04-09       Impact factor: 14.307

5.  A fail-safe mechanism for negative selection of isotype-switched B cell precursors is regulated by the Fas/FasL pathway.

Authors:  Jane Seagal; Efrat Edry; Zohar Keren; Nira Leider; Ofra Benny; Marcelle Machluf; Doron Melamed
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

6.  B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice.

Authors:  T Litzenburger; R Fässler; J Bauer; H Lassmann; C Linington; H Wekerle; A Iglesias
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.